[Abstract] [Full Text PDF] (in Japanese / 2057KB) [Members Only And Two Factor Auth.]

J.Jpn. Surg. Soc.. 104(10): 701-706, 2003


Feature topic

TREATMENT STRATEGY FOR HEPATIC METASTASES OF COLORECTAL CANCER

The Second Department of Surgery, Hamamatsu University School of Medicine, Hamamatsu, Japan

Satoshi Nakamura, Shohachi Suzuki

Over the past 25 years, 125 patients with colorectal liver metastases underwent 167 hepatectomies in our department. The 1- ,3- , and 5-year survival rates after the initial hepatectomy were 90%, 58%, and 51%, respectively, and those after repeated hepatectomy were 88%, 60%, and 42%, respectively. The predictive factors significantly associated with poor prognosis after initial hepatectomy were maximal diameter of metastasis (≧5 cm), distribution pattern in the liver (multiple bilobar), number of nodules (≧four), and presence of extrahepatic metastases. A disease-free interval of >6 months after initial hepatectomy was a significant factor for prolongation of survival after repeat hepatectomy. Patients with hilar node metastases at the initial hepatectomy did not receive a survival benefit from hepatectomy, while 5 patients underwent repeat hepatectomy with lymphadenectomy for remnant liver and hilar node metastases with a disease-free interval of >8 months and 4 of them survived for >5 years.
Our treatment strategies for colorectal hepatic metastases are as follows : 1) hepatectomy is the first choice for <4 liver metastases without extrahepatic disease ; 2) a careful evaluation for liver resection is performed for patients with ≧4 liver metastases receiving hepatic arterial infusion chemotherapy because of the high frequency of hepatic and/or extrahepatic recurrence after initial hepatectomy ; 3) the presence of hilar node metastases at the initial hepatectomy should be excluded from surgical indications : 4) simultaneous single metastasis limited to the lung is an indication for lung resection ; and 5) a suitable indication for repeat hepatectomy for hepatic recurrence is patients with a longer disease-free interval.
Aggressive surgery based on the optimum patient selection can contribute to clinical benefit, including long-term survival in patients with colorectal liver metastases.


<< To previous pageTo next page >>

To read the PDF file you will need Adobe Reader installed on your computer.